Literature DB >> 19622356

Cell cycle regulation of the mammalian CDK activator RINGO/Speedy A.

Ana Dinarina1, Patricia G Santamaria, Angel R Nebreda.   

Abstract

Cell cycle progression is regulated by cyclin-dependent kinases (CDKs), whose activation requires the binding of regulatory subunits named cyclins. RINGO/Speedy A is a mammalian protein that has no amino acid sequence homology with cyclins but can activate CDKs. Here we show that RINGO/Speedy A is a highly unstable protein whose expression and phosphorylation are periodically regulated during the cell cycle. RINGO/Speedy A is degraded by the proteasome and the process involves the ubiquitin ligase SCF(Skp2). Overexpression of a stabilized RINGO/Speedy A form results in the accumulation of high levels of RINGO/Speedy A at late stages of mitosis, which interfere with cytokinesis and chromosome decondensation. Our data show that tight regulation of RINGO/Speedy A is important for the somatic cell cycle.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622356     DOI: 10.1016/j.febslet.2009.07.028

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  Evolution of the Cdk-activator Speedy/RINGO in vertebrates.

Authors:  Sangeeta Chauhan; Xinde Zheng; Yue Ying Tan; Boon-Hui Tay; Shuhui Lim; Byrappa Venkatesh; Philipp Kaldis
Journal:  Cell Mol Life Sci       Date:  2012-07-05       Impact factor: 9.261

2.  Apoptosis and cell cycle regulatory effects of adenosine by modulation of GLI-1 and ERK1/2 pathways in CD44+ and CD24- breast cancer stem cells.

Authors:  S M Jafari; H R Joshaghani; M Panjehpour; M Aghaei; N Zargar Balajam
Journal:  Cell Prolif       Date:  2017-03-29       Impact factor: 6.831

3.  The cyclin-like protein Spy1/RINGO promotes mammary transformation and is elevated in human breast cancer.

Authors:  Mohammad Al Sorkhy; Rosa-Maria Ferraiuolo; Espanta Jalili; Agnes Malysa; Andreea R Fratiloiu; Bonnie F Sloane; Lisa A Porter
Journal:  BMC Cancer       Date:  2012-01-26       Impact factor: 4.430

4.  Inhibition of Nek2 by small molecules affects proteasome activity.

Authors:  Lingyao Meng; Kent Carpenter; Alexis Mollard; Hariprasad Vankayalapati; Steven L Warner; Sunil Sharma; Guido Tricot; Fenghuang Zhan; David J Bearss
Journal:  Biomed Res Int       Date:  2014-09-17       Impact factor: 3.411

5.  Differential proteomic profile of spermatogenic and Sertoli cells from peri-pubertal testes of three different bovine breeds.

Authors:  Utkarsh K Tripathi; Muhammad K M Aslam; Shashank Pandey; Samiksha Nayak; Shivani Chhillar; A Srinivasan; T K Mohanty; Prashant H Kadam; M S Chauhan; Savita Yadav; Arumugam Kumaresan
Journal:  Front Cell Dev Biol       Date:  2014-06-04

6.  The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting tamoxifen resistance.

Authors:  Rosa-Maria Ferraiuolo; Janice Tubman; Indrajit Sinha; Caroline Hamm; Lisa Ann Porter
Journal:  Oncotarget       Date:  2017-04-04

7.  A novel function for CDK2 activity at meiotic crossover sites.

Authors:  Nathan Palmer; S Zakiah A Talib; Priti Singh; Christine M F Goh; Kui Liu; John C Schimenti; Philipp Kaldis
Journal:  PLoS Biol       Date:  2020-10-19       Impact factor: 8.029

8.  Essential role of the Cdk2 activator RingoA in meiotic telomere tethering to the nuclear envelope.

Authors:  Petra Mikolcevic; Michitaka Isoda; Hiroki Shibuya; Ivan del Barco Barrantes; Ana Igea; José A Suja; Sue Shackleton; Yoshinori Watanabe; Angel R Nebreda
Journal:  Nat Commun       Date:  2016-03-30       Impact factor: 14.919

9.  The atypical cyclin-like protein Spy1 overrides p53-mediated tumour suppression and promotes susceptibility to breast tumourigenesis.

Authors:  Bre-Anne Fifield; Ingrid Qemo; Evie Kirou; Robert D Cardiff; Lisa Ann Porter
Journal:  Breast Cancer Res       Date:  2019-12-11       Impact factor: 6.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.